Tuesday, 22 November 2016｜Source：CHINA CHAMBER OF COMMERCEFOR IMPORT&EXPORT OF MEDICINES &HEALTH PRODUCTS｜Author：
We are very excited to have you participating in this year’s BioLink China Healthcare Industry Investment and Licensing Conference, hosted by CCCMHPIE, UBM Sinoexpo and co-organized by eChinaChem, Inc. and BFC Group. The event will take place at the San Francisco Hilton Airport hotel, located at 835 Airport Blvd., Burlingame CA 94010-9949. If you have any questions about the conference, please contact yumeng@cccmhpie.org.cn. Below are the detailed agenda of the conference:
Sunday, January 8, 2017
Language: English only
9:00 AM to 9:10 AM – Opening Remarks by Ming Xu, Deputy President of CCCMHPIE
Welcome Speech by Yinhang Yang, Deputy Consul of Chinese Consulate of San Francisco
9:10 AM to 10:10 AM – Investing in America
Many leading Chinese institutional investors are actively looking for investments in America, Europe and other developed countries. These investors look to enhance their portfolio investments of innovative products that meet the needs of the global market. This panel allows participants to gain insight into their investment strategy, their unique investment perspectives, and their current investment focus for global investments.
Moderator - David Chen, Managing Director, BFC Group
Panelists:
Mr. Kevin Chen, Partner and Head of Healthcare Investment, Sequoia Capital China
Dr. David Wang, Partner, OrbiMed China
Lily Han, Managing Director, Sunshine Insurance Group
Jeff Kindler, CEO of Centrixon. (Jeff was also the former CEO of Pfizer)
10:10 AM to 10:30 AM – Coffee Break
10:30 AM to 11:30 AM – Investment in China
Many of the MNC are also actively looking for deals in China. Afer the GSK incident, the MNC is looking at China deals in a different angle. We want to explore what the MNC is thinking about healthcare investment in China:
Moderator –Minghua Lu, CEO, eChinaChem, Inc.
Panelists
Samantha Du, Chairman & Chief Executive Officer, Zai Lab Limited
Peter Hua, Managing Partner of SB China Capital
Zhao Yining, Venture Partner, Lilly Asia Ventures
Guy Villax, CEO of Hovione Pharmaceutical
Dror Bashan, Global VP of MA and Business Development, Teva
Scott Smith, President of Celgene I&I
11:30 AM to 12:30 PM: Road Show Presentation
12:30 PM to 1:30 PM – Lunch Reception
1:30 PM to 4:00 PM: Road Show Presentation
4:00 PM to 5:00 PM – Optimal Deal Structures For Cross Border Transactions
Over the past 2 decades, many healthcare companies in China have grown rapidly and accumulated significant capital resources. They are now actively seeking innovative biomedical technologies to support their continued growth. The Chinese economy is hungry for promising products and technologies, and has begun looking to North America and Europe to expand their pipeline. Our panel will offer perspectives on how to successfully approach this vast market in terms of deal structure options for companies looking to secure capital, as well as licensing and distribution opportunities. With the right structure, US healthcare and life science companies can monetize their technology with little risk or cost.
Moderator: Kevin Chen, Partner, Sequoia Capital China
Panelists:
Wei Fu, Founding Partner, CBridge Capital
Michael Rosesal, Partner at Polsinelli
Dongmei Ji, Partner at GP Capital
Mr. Edward Zhou, Partner and Head of Healthcare Investment
5:00 PM to 7:00 PM – Cocktail Reception